ClinicalTrials.Veeva
Menu

Find clinical trials for Chronic Lymphocytic Leukemia in Rochester, MN

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

B-Cell Chronic Lymphocytic Leukemia
Leukemia
Lymphoid Leukemia
Lymphoma
B-Cell Lymphoma
Non-Hodgkin Lymphoma
Mantle-Cell Lymphoma

Chronic Lymphocytic Leukemia trials near Rochester, MN, USA:

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

monotherapy in participants with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL). This study will also all...

Enrolling
Chronic Lymphocytic Leukemia
Drug: Tocilizumab
Drug: Venetoclax

Phase 1

Roche
Roche

Rochester, Minnesota, United States and 17 other locations

Targeted drug therapies have greatly improved outcomes for patients with relapsed or refractory (R/R) chronic lymphocytic leukemia...

Active, not recruiting
Refractory Chronic Lymphocytic Leukemia
Relapsed Chronic Lymphocytic Leukemia
Drug: DTRM-555

Phase 2

Zhejiang DTRM Biopharma

Rochester, Minnesota, United States and 7 other locations

This study is designed to evaluate progression-free survival (PFS) endpoint for acalabrutinib versus (vs) ibrutinib in previously treated chronic...

Active, not recruiting
Chronic Lymphocytic Leukemia
Drug: Ibrutinib
Drug: Acalabrutinib

Phase 3

Acerta Pharma
Acerta Pharma

Rochester, Minnesota, United States and 130 other locations

Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients with Chronic Lymphocytic Leukemia...

Active, not recruiting
Chronic Lymphocytic Leukemia
Hypogammaglobulinemia
Biological: Panzyga
Other: Placebo

Phase 3

Octapharma

Rochester, Minnesota, United States and 83 other locations

This is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL...

Enrolling
Lymphoma, Small Lymphocytic
Leukemia, Lymphocytic, Chronic, B-Cell
Biological: JCAR017 (lisocabtagene maraleucel) + venetoclax
Biological: JCAR017 (lisocabtagene maraleucel) + ibrutinib

Phase 1, Phase 2

Juno Therapeutics

Rochester, Minnesota, United States and 67 other locations

The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm...

Enrolling
Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia
Drug: Venetoclax
Drug: Rituximab

Phase 3

Loxo Oncology
Loxo Oncology

Rochester, Minnesota, United States and 216 other locations

This phase I trial studies the side effects and best dose of romidepsin in treating patients with lymphoma, chronic lymphocytic leukemia...

Active, not recruiting
Recurrent Chronic Lymphocytic Leukemia
Refractory Chronic Lymphocytic Leukemia
Other: Pharmacological Study
Drug: Romidepsin

Phase 1

National Cancer Institute (NCI)
National Cancer Institute (NCI)

Rochester, Minnesota, United States and 11 other locations

This is an open-label, multi-center Phase 1/2 study of oral LOXO-305 (pirtobrutinib) in patients with CLL/SLL and NHL who have failed or are intolera...

Active, not recruiting
Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia
Drug: Venetoclax
Drug: Rituximab

Phase 1, Phase 2

Loxo Oncology
Loxo Oncology

Rochester, Minnesota, United States and 55 other locations

with obinutuzumab (Arm B) for the treatment of previously untreated chronic lymphocytic leukemia (CLL). Secondary objectiv...

Active, not recruiting
Chronic Lymphocytic Leukemia
Drug: Acalabrutinib
Drug: Chlorambucil

Phase 3

Acerta Pharma
Acerta Pharma

Rochester, Minnesota, United States and 154 other locations

This study aims to evaluate the safety, tolerability, pharmacodynamic, and pharmacokinetic (PK) of nemtabrutinib (formerly ARQ 531) tablets in select...

Active, not recruiting
Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia
Drug: Nemtabrutinib

Phase 1, Phase 2

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

Rochester, Minnesota, United States and 9 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems